About us AevisBio is a biotech company applying targeted protein modulator (TPM) technology to develop new therapeutics VIEW MORE

AevisBio is developing novel therapies for neurodegenerative diseases through synthetic neuroprotection — a dual strategy that suppresses neuroinflammation via ZFP91 degradation …

2019 AevisBio, Inc. founded in Gaithersburg, MD USA Korean Government grant (post-TIPS) awarded AevisBio entered into a CRADA with the NIA/NIH Life Science research Center …

In June of 2021, AevisBio, Institut Pasteur Korea (IPK) and National Institute on Aging (NIA) signed a Cooperative research agreement to develop potential new treatments for infectious …

AevisBio is a biotech company advancing Targeted Protein Modulator (TPM) technologies, with a focus on Molecular Glue (MG) development, to deliver first-in-class therapies that improve …

AevisBio, Inc., a company specializing in developing therapeutics for anti-inflammatory diseases has entered into a cooperative research and development agreement with the National …

In June of 2020, AevisBio and Korea Research Institute of Standards and Science (KRISS) announced a collaboration to develop technologies for treating infectious disease especially …

목록 이전글 AevisBio entered into a collaborative research with KRIBB 다음글 AevisBio entered into a CRADA with the NIA, part of the NIH

News Bio Research Center founded at Bio Venture Center, KRIBB 관리자 │ 2023-01-17 HIT 736 AevisBio opened Bio Research Center at BVC, Korea Research Institute of Bioscience and …

AevisBio, Inc., a company specializing in developing therapeutics for anti-inflammatory diseases, has entered into a collaborative research with the National Cancer Institute, an institute of the …